Literature DB >> 22061964

PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9.

Peta Bradbury1, Maha Mahmassani, Jessie Zhong, Kylie Turner, Andre Paul, Nicole M Verrills, Geraldine M O'Neill.   

Abstract

The mesenchymal mode of cancer cell invasion characterized by active adhesion turnover and a polarized actin cytoskeleton, is critically regulated by the adaptor protein NEDD9/HEF1/Cas-L. While it is known that NEDD9 is subject to extensive phosphorylation modification, the molecules that determine NEDD9 phosphorylation to stimulate adhesion turnover and mesenchymal cell morphologies are currently unknown. Earlier studies have suggested that the serine/threonine phosphatase PP2A regulates interconversion between a low molecular mass NEDD9 phosphoform and higher molecular mass phosphoforms. However, previous studies have used chemical inhibitors to block PP2A activity. In the present study we therefore aimed to specifically inhibit PP2A activity via siRNA and dominant negative approaches to investigate the effect of PP2A on interconversion between 115 kDa and 105 kDa NEDD9 and determine the functional consequence of PP2A activity for NEDD9 function. Strikingly, we find that while the phosphatase inhibitor Calyculin A indeed abrogates detachment-induced dephosphorylation of the 115 kDa NEDD9 phosphoform, PP2A depletion does not inhibit 115 kDa to 105 kDa interconversion. Our data suggest instead that PP2A targets discrete NEDD9 phosphorylation modifications separate to the events that mediate interconversion between the two forms. Functionally, PP2A depletion increases NEDD9 mediated cell spreading and mutation of S369 in the serine-rich region of NEDD9 to aspartate mimics this effect. Importantly, mutation of S369 to alanine abrogates the ability of dominant negative PP2A to increase NEDD9-mediated cell spreading. Collectively, our data reveal that the tumour suppressor PP2A may act via S369 to regulated NEDD9-mediated cell spreading. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22061964     DOI: 10.1016/j.bbamcr.2011.10.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Overexpression of Nedd9 is a prognostic marker of human gastric cancer.

Authors:  Qi Zhang; Huiju Wang; Yingyu Ma; Jun Zhang; Xujun He; Jie Ma; Zhong-Sheng Zhao
Journal:  Med Oncol       Date:  2014-06-07       Impact factor: 3.064

Review 2.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

3.  Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.

Authors:  Brandon C Jones; Laura C Kelley; Yuriy V Loskutov; Kristina M Marinak; Varvara K Kozyreva; Matthew B Smolkin; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2017-02-24       Impact factor: 5.852

4.  Agonist binding to β-adrenergic receptors on human airway epithelial cells inhibits migration and wound repair.

Authors:  Elizabeth R Peitzman; Nathan A Zaidman; Peter J Maniak; Scott M O'Grady
Journal:  Am J Physiol Cell Physiol       Date:  2015-10-21       Impact factor: 4.249

Review 5.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

6.  NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Authors:  Andriy O Samokhin; Thomas Stephens; Bradley M Wertheim; Rui-Sheng Wang; Sara O Vargas; Lai-Ming Yung; Minwei Cao; Marcel Brown; Elena Arons; Paul B Dieffenbach; Jason G Fewell; Majed Matar; Frederick P Bowman; Kathleen J Haley; George A Alba; Stefano M Marino; Rahul Kumar; Ivan O Rosas; Aaron B Waxman; William M Oldham; Dinesh Khanna; Brian B Graham; Sachiko Seo; Vadim N Gladyshev; Paul B Yu; Laura E Fredenburgh; Joseph Loscalzo; Jane A Leopold; Bradley A Maron
Journal:  Sci Transl Med       Date:  2018-06-13       Impact factor: 17.956

7.  NEDD9 stabilizes focal adhesions, increases binding to the extra-cellular matrix and differentially effects 2D versus 3D cell migration.

Authors:  Jessie Zhong; Jaime B Baquiran; Navid Bonakdar; Justin Lees; Yu Wooi Ching; Elena Pugacheva; Ben Fabry; Geraldine M O'Neill
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

8.  Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer.

Authors:  Si-Sen Zhang; Li-Hua Wu; Qing Liu; Kui-Sheng Chen; Xie-Fu Zhang
Journal:  Onco Targets Ther       Date:  2015-03-10       Impact factor: 4.147

9.  Tyrosine Y189 in the substrate domain of the adhesion docking protein NEDD9 is conserved with p130Cas Y253 and regulates NEDD9-mediated migration and focal adhesion dynamics.

Authors:  Jaime B Baquiran; Peta Bradbury; Geraldine M O'Neill
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

10.  High expression of HEF1 is associated with poor prognosis in urinary bladder carcinoma.

Authors:  Qi Zhang; Hui-Ju Wang; Da-Hong Zhang; Guo-Qing Ru; Xu-Jun He; Ying-Yu Ma
Journal:  Onco Targets Ther       Date:  2014-07-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.